CDX 014

Drug Profile

CDX 014

Alternative Names: CDX-014; CR 014-vcMMAE

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen; CuraGen Corporation
  • Developer Celldex Therapeutics Inc
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Membrane protein inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Renal cell carcinoma

Most Recent Events

  • 17 May 2018 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
  • 17 May 2018 Discontinued - Phase-I/II for Renal cell carcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
  • 07 Mar 2018 Celldex Therapeutics has a patent pending for CDX 014 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top